Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726498 | 1.00 | EGLN1 (0.70) | EGLN1EGLN2 | |
| SCHEMBL30394217 | 0.89 | EGLN1 (0.67) | EGLN1EGLN2 | |
| SCHEMBL28627889 | 0.88 | EGLN1 (0.66) | EGLN1EGLN2 | |
| SCHEMBL29898493 | 0.87 | EGLN1 (0.68) | EGLN1EGLN2 | |
| SCHEMBL22493055 | 0.87 | EGLN1 (0.65) | EGLN1EGLN2 | |
| SCHEMBL15268823 | 0.87 | EGLN1 (0.68) | EGLN1EGLN2 | |
| SCHEMBL22493051 | 0.87 | EGLN1 (0.65) | EGLN1EGLN2 | |
| SCHEMBL31238805 | 0.87 | EGLN1 (0.68) | EGLN1EGLN2 | |
| SCHEMBL29627762 | 0.86 | EGLN2 (0.64) | EGLN1EGLN2 | |
| Acetic Acid SCHEMBL28993792 | 0.86 | EGLN1 (0.64) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903532-A | Preparation method of roflumilast | 珠海优润医药科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115838354-B | Thyroid hormone receptor beta agonist compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024138317-A1 | THYROID HORMONE RECEPTOR β AGONIST COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2024-07-04 | — | — | WO | disclosed |
| CN-117486797-A | Key intermediate of roflumilast and preparation method of roflumilast | 传健生物医药(厦门)有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116903532-A | Preparation method of roflumilast | 珠海优润医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116903532-A | Preparation method of roflumilast | 珠海优润医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-112300073-B | Preparation method of isoquinoline derivative | 江西同和药业股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-110903242-B | Preparation method of Luo Shasi his intermediate | 四川科伦药物研究院有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-115594631-A | Rosemastat key intermediate and preparation method of Rosemastat intermediate | 安徽省庆云医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20220340532-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2022-10-27 | — | — | US | disclosed |
| EP-4010318-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021026307-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026307-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2021-02-11 | — | — | WO | disclosed |
| CN-112300073-A | Preparation method of isoquinoline derivative | 江西同和药业股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019174631-A1 | METHOD FOR PREPARING NORSTAT | 上海医药集团股份有限公司 | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340532-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | CYP2B6, CBR3, CYP3A4 | EGLN1 342/4885EGLN2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.